ArticleBMC gastroenterology2025
Efficacy of extracorporeal immunoadsorption therapy for removal of HBsAg.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of chronic hepatitis B (CHB) treatment is functional cure (FC). It refers to the removal of hepatitis B surface antigen (HBsAg) from the serum. However, this outcome is rare with current treatments due to the presence of integrated hepatitis B virus (HBV) DNA and intrahepatic covalently closed circular DNA (cccDNA). This study investigates the efficacy of removal of HBsAg using immunoadsorption. An immunosorbent was prepared by coupling anti-HBsAg monoclonal antibodies to agarose beads, selected from six candidates based on adsorption efficiency. Then the adsorbents were characterized by scanning electron microscopy (SEM) and energy dispersive spectrometer (EDS). V79 lung fibroblasts were used to determine the cytotoxicity of the immunosorbent through in vitro viability assays. The results indicated that the immunosorbent was non-cytotoxic. Static and dynamic adsorption studies in vitro demonstrated efficient HBsAg removal. To validate therapeutic potential, an extracorporeal circulation system equipped with the immunosorbent (10 ml sorbent column) was tested in rabbits injected with HBsAg-positive rabbit serum. This system selectively reduced serum HBsAg levels by 76.38 ± 1.37% and HBV DNA by 66.20 ± 0.85%. Given the absence of existing therapies capable of reducing HBsAg directly, our findings suggest that combining immunoadsorption with HBV drugs may serve as a novel therapeutic strategy—or at least provide a valuable adjunct—to advance functional cure efforts in CHB. Further clinical validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.